Asian markets traded mixed on Friday. Japan's Nikkei 225 fell 0.52%, and the Topix declined 0.57%.

US stock market ended higher on Thursday after two days of declines, led by banks and chip stocks.

Here's a table showing how US stocks performed on Thursday:

Source: Equitymaster

At present, the BSE Sensex is trading 375 points higher, and the NSE Nifty is trading 87 points higher.

Infosys, Tech Mahindra, and HCL Tech are among the top gainers today.

Sun Pharma, Eternal, and Bharti Airtel, on the other hand, are among the top losers today.

The BSE Midcap index is trading 0.3% higher, and the BSE Smallcap index is trading 0.1% higher.

Sectoral indices are trading mixed today, with stocks in the metal and telecommunication sector witnessed selling pressure. Meanwhile, stocks in realty sector and the banking sector witnessed buying.

The rupee is trading at Rs 90 against the US dollar.
 

BHEL Advances Vande Bharat Sleeper Programme

Bharat Heavy Electricals Ltd. (BHEL) has started supplying traction transformers for the Vande Bharat Sleeper Train project. These transformers are used to power the trains and are being supplied by a BHEL-led consortium along with TRSL.

The first set of underslung traction transformers was flagged off from BHEL's Jhansi plant through a virtual ceremony. Earlier, BHEL had already dispatched traction converters for this project from its Bengaluru unit.

BHEL said this marks an important step in its entry into the semi-high-speed train segment. The Vande Bharat Sleeper trains are designed to run at speeds up to 160 kmph, with a maximum design speed of 180 kmph.

The traction transformers are being sent to Kolkata, where the final assembly of the sleeper trains will take place. Apart from transformers, BHEL has also developed and manufactured traction motors at its Bhopal plant for the same project.

In a separate development, BHEL's Jhansi unit has received an order to supply Rail Borne Maintenance Vehicles (RBMVs). These vehicles are used for railway track maintenance and fall under specialised railway equipment.

This order supports government initiatives like Make in India and Aatmanirbhar Bharat, as the RBMVs will be manufactured in India, helping boost self-reliance in railway maintenance technology.
 

Transrail Lighting Receives Major New Orders

Transrail Lighting has won new orders worth Rs 5.27 billion (bn) across its Transmission & Distribution and Poles & Lighting businesses. These orders support the company's global expansion and strengthen its presence in the Middle East, North Africa (MENA), and Africa.

The company has also added HTLS re-conductoring manufacturing capability in India, expanding its product portfolio.

With these new wins, Transrail Lighting's total order inflows for FY26 have reached Rs 56.37 bn, showing strong momentum in both domestic and international markets.

Additionally, the company currently holds L1 (lowest bidder) status for projects worth over Rs 28 bn, providing strong visibility for future order inflows.
 

Biocon Completes Major Equity Fundraising

Biotech company Biocon has raised Rs 41.5 bn through a Qualified Institutions Placement (QIP). The fundraising was completed on 15 January 2026.

Under the QIP, Biocon issued 112.7 million equity shares with a face value of Rs 5 each to qualified institutional investors at an issue price of Rs 368.35 per share, as per its regulatory filing.

The QIP opened on 12 January 2026 and closed on 14 January 2026 and saw strong demand from both Indian and overseas institutional investors, showing confidence in the company's future growth.

Biocon will use the funds mainly to pay cash consideration to Mylan Inc. (Viatris) to acquire its remaining stake in Biocon Biologics, including repayment of related debt.

Earlier, the board approved a plan to buy out all minority shareholders, including Viatris, which will make Biocon Biologics a wholly owned subsidiary.

This move strengthens Biocon's focus on key therapeutic areas such as diabetes, oncology, and immunology, with a portfolio that includes biosimilars, insulin, generics, and GLP-1 products.

The acquisition and integration process is expected to be completed by 31 March 2026.

More By This Author: